{
  "doc_id": "9e32c903a26b045ee27b2d80e7feb779e01d8733991a579c3a34d3dacc56aaba",
  "chunk_entities": [
    {
      "chunk_id": "a99e434cca9478321f4e4df0f62e2c8d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "PDE4-inhibitors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obstructive airways disease",
          "context": "obstructive airways disease"
        }
      ]
    },
    {
      "chunk_id": "2b2ce862bf270bbb6f13a157eced763f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "PDE4-inhibitors: A novel, targeted therapy"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obstructive airways disease",
          "context": "targeted therapy for obstructive airways disease"
        }
      ]
    },
    {
      "chunk_id": "6f70c0e6ceb01d2457b69a48306d4cc8",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "PDE4-inhibitors: A novel, targeted therapy"
        },
        {
          "entity_type": "Disease",
          "entity_name": "obstructive airways disease",
          "context": "therapy for obstructive airways disease"
        }
      ]
    },
    {
      "chunk_id": "d05f126c25b11e1889fd080365b5f49b",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Chronic obstructive airways disease (COPD)",
          "context": "Chronic obstructive airways disease (COPD) represents a heterogeneous group of disorders"
        },
        {
          "entity_type": "Effect",
          "entity_name": "chronic inflammation",
          "context": "characterized by chronic inflammation of the proximal and the distal airways"
        },
        {
          "entity_type": "Effect",
          "entity_name": "airway remodeling",
          "context": "with features of airway remodeling and destruction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "destruction",
          "context": "with features of airway remodeling and destruction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fixed airway obstruction",
          "context": "These features present as fixed airway obstruction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperinflation",
          "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dyspnea",
          "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mucus hypersecretion",
          "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic cough",
          "context": "hyperinflation, dyspnea, mucus hypersecretion and chronic cough"
        },
        {
          "entity_type": "Effect",
          "entity_name": "structural changes",
          "context": "including structural changes and destruction of alveolar tissue"
        },
        {
          "entity_type": "Effect",
          "entity_name": "destruction of alveolar tissue",
          "context": "including structural changes and destruction of alveolar tissue"
        }
      ]
    },
    {
      "chunk_id": "577d177f1cd27b22ce2d1d8fc371d264",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Phosphodiesterase inhibition",
          "context": "Phosphodiesterase inhibition is an old concept"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "treatment of COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aminophylline",
          "context": "PDE)-inhibitors, aminophylline and theophylline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "theophylline",
          "context": "PDE)-inhibitors, aminophylline and theophylline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drug-interactions",
          "context": "limited by many drug-interactions"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "narrow dose-range",
          "context": "a narrow dose-range"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cardiovascular side effects",
          "context": "mostly cardiovascular and gastrointestinal side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gastrointestinal side effects",
          "context": "mostly cardiovascular and gastrointestinal side effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "theophylline",
          "context": "Whilst theophylline may non-selectively target PDE"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "high concentrations",
          "context": "albeit at high concentrations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of phosphoinositide 3 kinase",
          "context": "inhibition of phosphoinositide 3 kinase as a target"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory action",
          "context": "anti-inflammatory action of this drug"
        },
        {
          "entity_type": "Effect",
          "entity_name": "targeted therapy",
          "context": "enabling targeted therapy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "systemic side effects",
          "context": "potentially fewer (systemic) side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "non-selective PDE-inhibition",
          "context": "in contrast to non-selective PDE-inhibition"
        },
        {
          "entity_type": "Effect",
          "entity_name": "selectively targeting the PDE4-isoenzyme",
          "context": "selectively targeting the PDE4-isoenzyme"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "implicated in COPD"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disease modifying therapy",
          "context": "promising target for disease modifying therapy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "chronic airway inflammation",
          "context": "strong relationship between chronic airway inflammation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mucus hypersecretion",
          "context": "mucus hypersecretion with increased decline in lung function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased decline in lung function",
          "context": "increased decline in lung function"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "studies in COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "oral PDE4-inhibitors, cilomilast (Glaxo Smith Kline)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "cilomilast (Glaxo Smith Kline) and roflumilast (Nycomed)"
        }
      ]
    },
    {
      "chunk_id": "b8f1dac29022a4872ad9bc6d1d9f23e1",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "various PDE4-inhibitors appeared to be poor functional antagonists"
        },
        {
          "entity_type": "Effect",
          "entity_name": "relaxation of airway smooth muscle",
          "context": "produced modest relaxation of airway smooth muscle"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "study with cilomilast confirmed the previously observed improvements"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in lung function",
          "context": "observed improvements in lung function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in COPD exacerbations",
          "context": "showed a significant reduction in COPD exacerbations"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD exacerbations",
          "context": "reduction in COPD exacerbations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in quality of life scores",
          "context": "improvements in quality of life scores"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory activity",
          "context": "attributed to an anti-inflammatory activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "cilomilast has been shown to reduce the number of several pro-inflammatory cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce the number of several pro-inflammatory cells",
          "context": "cilomilast has been shown to reduce the number of several pro-inflammatory cells"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "implicated in the pathogenesis of COPD"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "approximately 40-50%",
          "context": "from subjects with COPD by approximately 40-50%"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in lung function",
          "context": "improvements in lung function were not maintained"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in lung function",
          "context": "explanations for the improvements in lung function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "exacerbation rates",
          "context": "exacerbation rates and quality of life"
        },
        {
          "entity_type": "Effect",
          "entity_name": "quality of life",
          "context": "quality of life additional to the indirect bronchodilator effect"
        },
        {
          "entity_type": "Effect",
          "entity_name": "bronchodilator effect",
          "context": "indirect bronchodilator effect of cilomilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "bronchodilator effect of cilomilast seen in a majority"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modulation of sensory nerve function",
          "context": "attributed to a modulation of sensory nerve function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in contraction of airway smooth muscle",
          "context": "a reduction in contraction of airway smooth muscle"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in airflow",
          "context": "leading to improvements in airflow and symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements in symptoms",
          "context": "improvements in airflow and symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cyclic AMP",
          "context": "elevating the level of cyclic AMP in airway epithelial cells"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rehydration of the epithelial periciliary layer",
          "context": "promote rehydration of the epithelial periciliary layer"
        },
        {
          "entity_type": "Effect",
          "entity_name": "facilitating mucociliary clearance of mucus and bacteria",
          "context": "facilitating mucociliary clearance of mucus and bacteria"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "PDE4 inhibitors can reduce mucus production"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduce mucus production",
          "context": "PDE4 inhibitors can reduce mucus production"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase ciliary beat frequency",
          "context": "increase ciliary beat frequency of airway epithelial cells"
        }
      ]
    },
    {
      "chunk_id": "da025e1e40f7f7ab07600fa502c279bc",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "studies with cilomilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "efficacy",
          "context": "clinical efficacy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "safety",
          "context": "safety data"
        },
        {
          "entity_type": "Effect",
          "entity_name": "efficacy",
          "context": "efficacy endpoints"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvement in lung function",
          "context": "significant improvement in lung function"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "24 weeks",
          "context": "following 24 weeks of treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "treatment with cilomilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gastrointestinal side effects",
          "context": "gastrointestinal side effects"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2 weeks",
          "context": "within the first 2 weeks of treatment"
        }
      ]
    },
    {
      "chunk_id": "ca56fecc0c58a63afb012aa76d83baf2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "development of cilomilast was terminated"
        }
      ]
    },
    {
      "chunk_id": "12e35efaee014f47451619f7b5f942e1",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "failure of cilomilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "targeting PDE4"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "treatment of COPD"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PDE4-inhibition",
          "context": "sustained PDE4-inhibition"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "PDE4-inhibitor roflumilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PDE4-inhibitor",
          "context": "highly potent, once daily PDE4-inhibitor"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "once daily",
          "context": "once daily PDE4-inhibitor"
        }
      ]
    },
    {
      "chunk_id": "678229b8f4cae32364deccabdb6d285e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast: pharmacokinetics"
        }
      ]
    },
    {
      "chunk_id": "bd1d5728b17cf842c58e616ac92b9f31",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast is rapidly absorbed"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "250-1000 mcg",
          "context": "Over a dose-range of 250-1000 mcg"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast shows linearly dose-proportional pharmacokinetics"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast is rapidly metabolized by CYP3A4 and CYP1A2 enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CYP3A4",
          "context": "metabolized by CYP3A4 and CYP1A2 enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CYP1A2",
          "context": "metabolized by CYP3A4 and CYP1A2 enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-oxide",
          "context": "N-oxide, being the major metabolite of roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "major metabolite of roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 isoenzymes",
          "context": "possesses selectivity for the PDE4 isoenzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 subtypes",
          "context": "not for PDE4 subtypes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "Both roflumilast and N-oxide are mainly excreted"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-oxide",
          "context": "Both roflumilast and N-oxide are mainly excreted"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "between roflumilast and other (COPD-related) pharmacological treatments"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "(COPD-related) pharmacological treatments"
        }
      ]
    },
    {
      "chunk_id": "4b04451fef8aaea9305e782c5693abb7",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "exacerbations",
          "context": "exacerbations (p=0.0114)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "severe COPD (GOLD stages II to IV)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "received roflumilast for one year"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "one year",
          "context": "roflumilast for one year"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvement in baseline FEV1",
          "context": "significant improvement in baseline FEV1"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in exacerbation rates",
          "context": "modest reduction in exacerbation rates"
        }
      ]
    },
    {
      "chunk_id": "c674c321267d06ecbf909fb4707589a9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "randomized controlled trials (RCT) with roflumilast"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "moderate to severe COPD"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lung function",
          "context": "effect on lung function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "efficacy of roflumilast"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD-exacerbations",
          "context": "prevention and treatment of COPD-exacerbations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prevention",
          "context": "prevention and treatment of COPD-exacerbations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "treatment",
          "context": "prevention and treatment of COPD-exacerbations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "safety/tolerability",
          "context": "safety/tolerability"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "studies in COPD"
        },
        {
          "entity_type": "Effect",
          "entity_name": "treatment",
          "context": "effects of treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "treatment with roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "roflumilast versus placebo"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "addition to salmeterol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tiotropium",
          "context": "or tiotropium"
        },
        {
          "entity_type": "Disease",
          "entity_name": "moderate to severe COPD",
          "context": "patients with moderate to severe COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "either roflumilast (n=466)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "or placebo (n=467)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "combination with salmeterol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "either roflumilast (n=371)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "or placebo (n=372)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tiotropium",
          "context": "combination with tiotropium"
        },
        {
          "entity_type": "Compound",
          "entity_name": "inhaled corticosteroids",
          "context": "using inhaled corticosteroids"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic cough",
          "context": "symptomatic patients with chronic cough"
        },
        {
          "entity_type": "Disease",
          "entity_name": "sputum production",
          "context": "and sputum production"
        },
        {
          "entity_type": "Compound",
          "entity_name": "short-acting bronchodilators",
          "context": "use of short-acting bronchodilators"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast was associated with consistent and sustained improvements"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improvements",
          "context": "sustained improvements in both the pre- and post-bronchodilator FEV1"
        },
        {
          "entity_type": "Effect",
          "entity_name": "FEV1",
          "context": "pre- and post-bronchodilator FEV1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "In the salmeterol-combination"
        },
        {
          "entity_type": "Effect",
          "entity_name": "FEV1",
          "context": "increase in pre-bronchodilator FEV1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "FEV1 versus placebo"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tiotropium",
          "context": "in the tiotropium-combination"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "patients on roflumilast tended to have fewer exacerbations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fewer exacerbations",
          "context": "tended to have fewer exacerbations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "larger in the roflumilast-arm"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "in the salmeterol-roflumilast-arm"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast-related side effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "side effects",
          "context": "roflumilast-related side effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nausea",
          "context": "consisted of nausea"
        },
        {
          "entity_type": "Disease",
          "entity_name": "diarrhea",
          "context": "diarrhea and mild weight loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mild weight loss",
          "context": "mild weight loss"
        }
      ]
    },
    {
      "chunk_id": "8fbd93fb1b66921dca70e07abddb636a",
      "entities": [
        {
          "entity_type": "Dosage",
          "entity_name": "30-50%",
          "context": "reflecting a 30-50% suppression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppression of inflammatory cell numbers",
          "context": "30-50% suppression of inflammatory cell numbers"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "40-50%",
          "context": "reduced ... by approximately 40-50%"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "an anti-inflammatory mechanism"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "cilomilast reduced the level"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TNF-alpha",
          "context": "reduced the level of TNF-alpha"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "25% decrease",
          "context": "TNF-alpha (25% decrease)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GMCSF",
          "context": "GMCSF (46% decrease)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "46% decrease",
          "context": "GMCSF (46% decrease)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neutrophil chemotactic factors",
          "context": "and neutrophil chemotactic factors"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "35% decrease",
          "context": "factors (35% decrease)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "IL-8",
          "context": "no effect on IL-8 released"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "epithelial cells from COPD patients"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of the inflammatory response",
          "context": "greater inhibition of the inflammatory response"
        }
      ]
    },
    {
      "chunk_id": "a4c8875444a9e50f272646ddc96fe9b4",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "ICS",
          "context": "combination therapy of ICS and LABA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "LABA",
          "context": "combination therapy of ICS and LABA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "relaxation of airway smooth muscle",
          "context": "relaxation of airway smooth muscle"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory action",
          "context": "synergistic or additive anti-inflammatory action"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "between salmeterol versus combination therapy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory activity",
          "context": "associated with anti-inflammatory activity"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "12-13 weeks",
          "context": "after 12-13 weeks of treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone",
          "context": "monotherapy with fluticasone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone",
          "context": "effect of fluticasone monotherapy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction (of airway neutrophil numbers)",
          "context": "reports of a reduction [48]"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase (of airway neutrophil numbers)",
          "context": "and increase [52]"
        },
        {
          "entity_type": "Effect",
          "entity_name": "corticosteroid resistance",
          "context": "corticosteroid resistance in patients with COPD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "patients with COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "histone deacetylase (HDAC)-2",
          "context": "activity of histone deacetylase (HDAC)-2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduction in the activity of histone deacetylase (HDAC)-2",
          "context": "resulting in reduction in the activity of histone deacetylase (HDAC)-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "HDAC2",
          "context": "increasing the HDAC2-activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-inhibitors",
          "context": "by PDE-inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphoinositide 3 kinase-delta inhibitors",
          "context": "phosphoinositide 3 kinase-delta inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "macrolides",
          "context": "and macrolides"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reversal of corticosteroid resistance",
          "context": "result in a reversal of corticosteroid resistance"
        }
      ]
    },
    {
      "chunk_id": "241527c44b0da752d04e8ae195c2b217",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "systemically administered PDE4-inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "produce nausea"
        },
        {
          "entity_type": "Effect",
          "entity_name": "headache",
          "context": "produce nausea and headache"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "shunted off cilomilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "eliminated for roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "subtype-selective PDE4-inhibitors",
          "context": "develop subtype-selective PDE4-inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D isoenzymes",
          "context": "inhibition of the PDE4D isoenzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "brain-penetrant PDE4-",
          "context": "selective brain-penetrant PDE4-"
        }
      ]
    },
    {
      "chunk_id": "a5696a27958fdb2fe8dcc7c0e7c8b9e1",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "inhibitors",
          "context": "inhibitors that are devoid of emesis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "emesis",
          "context": "devoid of emesis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D",
          "context": "targeting of PDE4D"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "interest to COPD"
        }
      ]
    },
    {
      "chunk_id": "92ee628ff47e1bebfed8efff9dc3c924",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "PDE4-inhibition",
          "context": "achieve more substantial PDE4-inhibition in the lung"
        },
        {
          "entity_type": "Disease",
          "entity_name": "respiratory disease",
          "context": "evaluated in respiratory disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "UK-500,001",
          "context": "A highly potent PDE4-inhibitor, UK-500,001"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "patients with moderate to severe COPD"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "6 weeks",
          "context": "after 6 weeks of treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GSK256066",
          "context": "the inhaled PDE4-inhibitor, GSK256066"
        },
        {
          "entity_type": "Effect",
          "entity_name": "attenuate the acute and late phase allergic airway response",
          "context": "was shown to attenuate the acute and late phase allergic airway response"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1 week",
          "context": "after 1 week of treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "clinically effective in COPD"
        }
      ]
    },
    {
      "chunk_id": "efbf083d2a7a9f13233ec0b391a4ce96",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "mixed PDE-inhibitors",
          "context": "using mixed PDE-inhibitors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "treatment of COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "that PDE4-inhibitors per se"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting macrophage function",
          "context": "poor at inhibiting macrophage function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE3",
          "context": "that PDE3 is also present"
        },
        {
          "entity_type": "Effect",
          "entity_name": "bronchodilator effects",
          "context": "produce bronchodilator effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "promote chloride ion secretion",
          "context": "promote chloride ion secretion"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chloride ion",
          "context": "promote chloride ion secretion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "additive actions",
          "context": "have additive or potentially synergistic actions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "synergistic actions",
          "context": "potentially synergistic actions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mixed PDE3/4 inhibitors",
          "context": "early mixed PDE3/4 inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory activity",
          "context": "coupled with anti-inflammatory activity"
        }
      ]
    },
    {
      "chunk_id": "019e08c07d722aa9b0d108941fa07228",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE7",
          "context": "targeting PDE7 may also be beneficial"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "pathogenesis of COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chemical inhibitor",
          "context": "targeting PDE7 with a chemical inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modify cell function",
          "context": "failed to modify cell function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhance the inhibitory action",
          "context": "appeared to enhance the inhibitory action"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 selective inhibitor",
          "context": "inhibitory action of a PDE4 selective inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "Targeting both PDE4 and PDE7"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE7",
          "context": "Targeting both PDE4 and PDE7"
        },
        {
          "entity_type": "Compound",
          "entity_name": "antisense oligonucleotides",
          "context": "PDE7 with antisense oligonucleotides"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppressed various indices of airway inflammation",
          "context": "suppressed various indices of airway inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "airway inflammation",
          "context": "indices of airway inflammation"
        }
      ]
    },
    {
      "chunk_id": "fb3aee050dcc2b237b5adb8e4c8661de",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "oligonucleotides",
          "context": "component oligonucleotides"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitory activity",
          "context": "provided a greater inhibitory activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE-inhibitors",
          "context": "development of mixed PDE-inhibitors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "treatment of COPD"
        }
      ]
    },
    {
      "chunk_id": "fd7aebf77c1caac407be5ee5c8a6a308",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "theophylline",
          "context": "PDE-inhibitor theophylline"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PDE-inhibitor",
          "context": "non-selective PDE-inhibitor theophylline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "PDE4-inhibitors cilomilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "PDE4-inhibitors cilomilast and roflumilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PDE4-inhibitors",
          "context": "selective PDE4-inhibitors cilomilast and roflumilast"
        },
        {
          "entity_type": "Effect",
          "entity_name": "side effects",
          "context": "cause substantially less side effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "roflumilast-related adverse events"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse events",
          "context": "roflumilast-related adverse events"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "reported by COPD-patients"
        },
        {
          "entity_type": "Effect",
          "entity_name": "adverse events",
          "context": "central adverse events"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "(nausea, headache, insomnia)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "headache",
          "context": "(nausea, headache, insomnia)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "insomnia",
          "context": "(nausea, headache, insomnia)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "gastro-intestinal side effects",
          "context": "gastro-intestinal side effects (diarrhea)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "diarrhea",
          "context": "gastro-intestinal side effects (diarrhea)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "(modest) weight loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Adverse events",
          "context": "Adverse events mostly became evident"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "patient withdrawal in the roflumilast-arms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cardiac toxicity",
          "context": "no clinically relevant cardiac toxicity"
        }
      ]
    },
    {
      "chunk_id": "5924c502444e71f851db89ce6bbf22a9",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "diarrhea",
          "context": "the most common side effects were diarrhea and weight loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "the most common side effects were diarrhea and weight loss"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "67% in the roflumilast arm"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "weight loss was reported, with a mean of 2.1 kg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2.1 kg",
          "context": "with a mean of 2.1 kg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2.0 kg",
          "context": "similar mean weight loss of 2.0 and 1.8 kg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.8 kg",
          "context": "similar mean weight loss of 2.0 and 1.8 kg"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "The largest absolute weight loss was seen"
        },
        {
          "entity_type": "Disease",
          "entity_name": "BMI >30",
          "context": "patients with a BMI >30"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "this weight loss could be ascribed primarily to fat loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "fat loss",
          "context": "ascribed primarily to fat loss"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "systemic anti-inflammatory potential of roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "potential of roflumilast"
        }
      ]
    },
    {
      "chunk_id": "a1f64eddcf4fe4ff7c23eb53177b72df",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "In the COPD safety pooled analysis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "12,000 COPD patients"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "patients on roflumilast 250 \u00b5g"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "250 \u00b5g",
          "context": "roflumilast 250 \u00b5g"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "patients on roflumilast 500 \u00b5g"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "500 \u00b5g",
          "context": "roflumilast 500 \u00b5g"
        },
        {
          "entity_type": "Compound",
          "entity_name": "placebo",
          "context": "patients on placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicides",
          "context": "3 cases of suicides were reported"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "receiving roflumilast treatment"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "250 \u00b5g",
          "context": "1 on 250 \u00b5g"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "500 \u00b5g",
          "context": "2 on 500 \u00b5g"
        },
        {
          "entity_type": "Disease",
          "entity_name": "depression",
          "context": "pre-existent depression among these patients"
        }
      ]
    },
    {
      "chunk_id": "19cd1e480f56ae223d1eff50703111e3",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "among COPD patients"
        }
      ]
    },
    {
      "chunk_id": "53dd7d4526a10744248aa8069e1e8ff7",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "anti-inflammatory effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "effects of roflumilast"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "roflumilast in COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "PDE4-inhibitors reverse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "corticosteroid resistance",
          "context": "reverse corticosteroid resistance"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "do PDE4-inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ICS",
          "context": "combination with ICS"
        },
        {
          "entity_type": "Effect",
          "entity_name": "disease-modifying properties",
          "context": "possess disease-modifying properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "prevention of the increased decline in lung function",
          "context": "prevention of the increased decline in lung function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modulation of the systemic effects",
          "context": "modulation of the systemic effects in COPD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "systemic effects in COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4-inhibitors",
          "context": "combinations with) PDE4-inhibitors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decrease the morbidity",
          "context": "decrease the morbidity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decrease the mortality",
          "context": "decrease the morbidity and mortality"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "phenotypes of) COPD"
        }
      ]
    },
    {
      "chunk_id": "110c0f090ab3d12c1bfab80acc2e6228",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "combinations of) roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ICS",
          "context": "roflumilast and ICS"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "COPD phenotypes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "preventive potential",
          "context": "test its preventive potential"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "pharmacological COPD management"
        }
      ]
    },
    {
      "chunk_id": "f21327c668f6aba21135e4efc8270b3d",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "bronchoreversibility",
          "context": "correlates of bronchoreversibility"
        },
        {
          "entity_type": "Disease",
          "entity_name": "emphysema",
          "context": "severe emphysema"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Chronic Obstructive Pulmonary Disease",
          "context": "Prevention of Chronic Obstructive Pulmonary Disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "small-airway obstruction",
          "context": "nature of small-airway obstruction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "obstruction in chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "Mediators of chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "asthma",
          "context": "network in asthma"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "asthma and chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "cells and chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Systemic inflammation",
          "context": "Systemic inflammation and comorbidity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "comorbidity",
          "context": "inflammation and comorbidity in COPD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "comorbidity in COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "corticosteroids",
          "context": "inhaled corticosteroids"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "corticosteroids in chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "Patients with COPD"
        }
      ]
    },
    {
      "chunk_id": "852cf327078a543563d0bbb0fbd1ce4f",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "approach against PDE4"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE7",
          "context": "and PDE7 reduces"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces lung inflammation",
          "context": "reduces smoke-induced lung inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "lung inflammation",
          "context": "smoke-induced lung inflammation"
        }
      ]
    },
    {
      "chunk_id": "1a23212ad32defc30b5b3252ee96f4b2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 inhibitor",
          "context": "the phosphodiesterase 4 inhibitor, cilomilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "the phosphodiesterase 4 inhibitor, cilomilast (15 mg)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "single dose",
          "context": "Does a single dose of the phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "15 mg",
          "context": "cilomilast (15 mg)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "bronchodilation",
          "context": "induce bronchodilation in patients"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "patients with chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "59dc58c6e7f2d089a9f39db1e2ada317",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase isozymes",
          "context": "Phosphodiesterase isozymes modulating inherent tone"
        },
        {
          "entity_type": "Effect",
          "entity_name": "modulating inherent tone",
          "context": "modulating inherent tone in human airways"
        }
      ]
    },
    {
      "chunk_id": "72c4c562d6f1298f0247a37cdea5be1c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase isozymes",
          "context": "functional role of phosphodiesterase isozymes in human airway smooth muscle"
        }
      ]
    },
    {
      "chunk_id": "17c1ee2f2ae3cf1232090ce9cf825084",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 inhibitor",
          "context": "the phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "cilomilast (15 mg)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "single dose",
          "context": "Does a single dose"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "15 mg",
          "context": "cilomilast (15 mg)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "bronchodilation",
          "context": "induce bronchodilation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "patients with chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "11a44f329fcd36113c0e17e623392e5b",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "activation",
          "context": "Dynamic activation of cystic fibrosis transmembrane conductance regulator"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cystic fibrosis",
          "context": "Dynamic activation of cystic fibrosis transmembrane conductance regulator"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibitors",
          "context": "type 3 and type 4D phosphodiesterase inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "type 3 phosphodiesterase inhibitors",
          "context": "type 3 and type 4D phosphodiesterase inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "type 4D phosphodiesterase inhibitors",
          "context": "type 3 and type 4D phosphodiesterase inhibitors"
        }
      ]
    },
    {
      "chunk_id": "c49b4d51cc23f718748f08945558e701",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibitors",
          "context": "selective phosphodiesterase inhibitors on mucociliary activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 4",
          "context": "Phosphodiesterase 4 inhibition decreases MUC5AC expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MUC5AC",
          "context": "decreases MUC5AC expression induced by epidermal growth factor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "epidermal growth factor",
          "context": "MUC5AC expression induced by epidermal growth factor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cilomilast",
          "context": "efficacy and safety of cilomilast in COPD"
        },
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 inhibitor",
          "context": "a selective, oral phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mucociliary activity",
          "context": "effect of selective phosphodiesterase inhibitors on mucociliary activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition",
          "context": "Phosphodiesterase 4 inhibition decreases MUC5AC expression"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases MUC5AC expression",
          "context": "inhibition decreases MUC5AC expression induced by epidermal growth factor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "selective",
          "context": "a selective, oral phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "oral",
          "context": "a selective, oral phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "Roflumilast--an oral anti-inflammatory treatment"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "cilomilast in COPD"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "development for chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "severe chronic obstructive pulmonary disease",
          "context": "roflumilast in severe chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "symptomatic chronic obstructive pulmonary disease",
          "context": "Roflumilast in symptomatic chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "6cc6e7e03a095713ef7c4d3c9ec42092",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast in moderate-to-severe chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "bronchodilators",
          "context": "treated with longacting bronchodilators"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "moderate-to-severe chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "05ed8adf6fdbe0c5d48ccfb61f912859",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Anti-inflammatory effects",
          "context": "Anti-inflammatory effects of salmeterol/fluticasone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "effects of salmeterol/fluticasone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone",
          "context": "salmeterol/fluticasone, tiotropium/fluticasone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tiotropium",
          "context": "tiotropium/fluticasone or tiotropium"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "tiotropium in COPD"
        }
      ]
    },
    {
      "chunk_id": "0a9e34fed0d9214e0939ccf1189daf17",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone",
          "context": "Effect of fluticasone with and without salmeterol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "salmeterol",
          "context": "with and without salmeterol on pulmonary outcomes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pulmonary outcomes",
          "context": "salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "pulmonary outcomes in chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "3fc21b7771b775bc80c224553d7f9770",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Salmeterol",
          "context": "Salmeterol and fluticasone propionate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone propionate",
          "context": "Salmeterol and fluticasone propionate"
        },
        {
          "entity_type": "Effect",
          "entity_name": "survival",
          "context": "and survival in chronic obstructive pulmonary disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "in chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "c3db582bed490da8180535cd6b2463bb",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "fluticasone propionate",
          "context": "Effects of fluticasone propionate"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "cells in COPD"
        }
      ]
    },
    {
      "chunk_id": "03794989fec9cfce42750e273687fbdf",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "glucocorticoid",
          "context": "glucocorticoid control of inflammation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anti-inflammatory",
          "context": "control of inflammation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "inflammation",
          "context": "control of inflammation"
        }
      ]
    },
    {
      "chunk_id": "0639a30770cfda8a03530e87691800c0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "zardaverine",
          "context": "inhaled zardaverine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Bronchodilatory effect",
          "context": "Bronchodilatory effect of inhaled zardaverine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "asthma",
          "context": "patients with asthma"
        }
      ]
    },
    {
      "chunk_id": "2ceab326b96221c13f60c9a0ca1d6e33",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "zardaverine",
          "context": "the mixed phosphodiesterase III/IV inhibitor, zardaverine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase III/IV inhibitor",
          "context": "mixed phosphodiesterase III/IV inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "airway function",
          "context": "Effects ... on airway function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "phosphodiesterase III/IV inhibitor"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic airflow obstruction",
          "context": "patients with chronic airflow obstruction"
        }
      ]
    },
    {
      "chunk_id": "ede7e2b8690aff92477cc123b87a92bb",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "roflumilast",
          "context": "Effects of roflumilast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4 inhibitor",
          "context": "a phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "phosphodiesterase 4 inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "on body composition",
          "context": "on body composition"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease",
          "context": "in chronic obstructive pulmonary disease"
        }
      ]
    },
    {
      "chunk_id": "0e69cb76d1afa7d5470bf5357aaaf0ad",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase type 4 inhibitors",
          "context": "Phosphodiesterase type 4 inhibitors cause proinflammatory effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "proinflammatory effects",
          "context": "cause proinflammatory effects in vivo"
        }
      ]
    },
    {
      "chunk_id": "5697ce8ba96c3e8cef46bff87e6ec1e3",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Cilomilast",
          "context": "Cilomilast reduces CD8+ T-lymphocytes"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces CD8+ T-lymphocytes and macrophages",
          "context": "Cilomilast reduces CD8+ T-lymphocytes and macrophages"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic obstructive pulmonary disease (COPD)",
          "context": "patients with chronic obstructive pulmonary disease (COPD)"
        }
      ]
    },
    {
      "chunk_id": "6c73b4f133f163528a6a109ecab7e777",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4",
          "context": "function of phosphodiesterase 4 (PDE4) subtypes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4",
          "context": "phosphodiesterase 4 (PDE4) subtypes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PDE4D",
          "context": "predominant role of PDE4D"
        }
      ]
    },
    {
      "chunk_id": "26034bb27641302618168c9a16ae34d0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibitors",
          "context": "Effects of phosphodiesterase inhibitors"
        }
      ]
    },
    {
      "chunk_id": "5b988a712f198d2726111ac597494a61",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "anti-asthma",
          "context": "The effects of anti-asthma drugs"
        },
        {
          "entity_type": "Disease",
          "entity_name": "asthma",
          "context": "The effects of anti-asthma drugs"
        }
      ]
    },
    {
      "chunk_id": "15c106a338f97b45a48b612a36b4b71a",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast inhibits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits leukocyte-endothelial cell interactions",
          "context": "Roflumilast inhibits leukocyte-endothelial cell interactions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits expression of adhesion molecules",
          "context": "expression of adhesion molecules"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits microvascular permeability",
          "context": "microvascular permeability"
        }
      ]
    },
    {
      "chunk_id": "05b03484accfb112df01bd4673317e6e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "TGF-beta",
          "context": "Inhibition of TGF-beta induced lung fibroblast"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase inhibiting drugs",
          "context": "conversion by phosphodiesterase inhibiting drugs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "activators of soluble guanylyl cyclase",
          "context": "and activators of soluble guanylyl cyclase"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Inhibition",
          "context": "Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lung fibroblast to myofibroblast conversion",
          "context": "Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion"
        }
      ]
    },
    {
      "chunk_id": "149e026769c9c50f949729918cf141ef",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 3",
          "context": "Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Phosphodiesterase 4",
          "context": "Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "major cAMP metabolizing enzymes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "insulin",
          "context": "responsible for insulin secretion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "insulin secretion",
          "context": "responsible for insulin secretion"
        }
      ]
    },
    {
      "chunk_id": "8a5a8abc41753706c14379b55a4c2c02",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "phosphodiesterase 4",
          "context": "antilipolytic role of phosphodiesterase 4"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antilipolytic",
          "context": "antilipolytic role of phosphodiesterase 4"
        }
      ]
    },
    {
      "chunk_id": "60879d61512f50d5d98031736e7105e0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cyclic nucleotide phosphodiesterases",
          "context": "The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis."
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulation of adipocyte lipolysis",
          "context": "The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis."
        }
      ]
    },
    {
      "chunk_id": "96f57fc8871f2121af7c9a2084cc4efd",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "1PDE4 subtype mRNA",
          "context": "1PDE4 subtype mRNA expression"
        }
      ]
    },
    {
      "chunk_id": "247662ef3273920a15f69a9233e9a680",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "PDE4 inhibitors",
          "context": "clinical trials with PDE4 inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "long acting bronchodilators",
          "context": "and long acting bronchodilators"
        },
        {
          "entity_type": "Disease",
          "entity_name": "COPD",
          "context": "bronchodilators in COPD"
        }
      ]
    },
    {
      "chunk_id": "4d392be27b2149bd3cf1077899a18770",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Cilomilast",
          "context": "Cilomilast 5 mg bid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cilomilast",
          "context": "Cilomilast 10 mg bid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cilomilast",
          "context": "Cilomilast 15 mg bid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast 0.25 mg"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast 0.5 mg"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase",
          "context": "160 mL increase over placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase",
          "context": "40 mL increase over placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decrease",
          "context": "39% decrease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase",
          "context": "64 and 88 ml increase over placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increase",
          "context": "74 and 97 ml increase over placebo"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5 mg bid",
          "context": "Cilomilast 5 mg bid"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "10 mg bid",
          "context": "Cilomilast 10 mg bid"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "15 mg bid",
          "context": "Cilomilast 15 mg bid"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.25 mg",
          "context": "Roflumilast 0.25 mg"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.5 mg",
          "context": "Roflumilast 0.5 mg"
        }
      ]
    },
    {
      "chunk_id": "545e791f7c21d448db7de6e97f7e3c73",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Roflumilast",
          "context": "Roflumilast 0.5 mg od"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.5 mg od",
          "context": "Roflumilast 0.5 mg od"
        },
        {
          "entity_type": "Effect",
          "entity_name": "34 % decrease",
          "context": "Exacerbations34 % decrease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Exacerbations",
          "context": "Exacerbations34 % decrease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "40 %",
          "context": "40 %Prebronchodilator FEV1"
        },
        {
          "entity_type": "Disease",
          "entity_name": "GOLD IV",
          "context": "Exacerbations: (GOLD IV)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "36 ml increase",
          "context": "36 ml increase over placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "39 ml increase",
          "context": "39 ml increase over placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "3 units cf placebo",
          "context": "3 units cf placebo"
        },
        {
          "entity_type": "Effect",
          "entity_name": "36% lower",
          "context": "36% lower"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Salmeterol",
          "context": "Salmeterol both groups"
        },
        {
          "entity_type": "Effect",
          "entity_name": "50 %",
          "context": "50 %Prebronchodilator FEV1"
        },
        {
          "entity_type": "Effect",
          "entity_name": "49 ml increase",
          "context": "49 ml increase over placebo/salmeterol"
        },
        {
          "entity_type": "Effect",
          "entity_name": "60 ml increase",
          "context": "60 ml increase over placebo/salmeterol"
        },
        {
          "entity_type": "Disease",
          "entity_name": "exacerbations",
          "context": "Mean rate of exacerbations(mild, moderate, severe)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "NS cf placebo/salmeterol",
          "context": "NS cf placebo/salmeterol"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Dyspnea index",
          "context": "Dyspnea index"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tiotropium",
          "context": "Tiotropium both groups"
        },
        {
          "entity_type": "Effect",
          "entity_name": "80 ml increase",
          "context": "80 ml increase over placebo/tiotropium"
        },
        {
          "entity_type": "Effect",
          "entity_name": "81 ml increase",
          "context": "81 ml increase over placebo/tiotropium"
        },
        {
          "entity_type": "Effect",
          "entity_name": "NS cf placebo/tiotropium",
          "context": "NS cf placebo/tiotropium"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Dyspnea index (TDI focal)",
          "context": "Dyspnea index (TDI focal)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "0.4 units/2.6 units significantly better",
          "context": "0.4 units/2.6 units significantly better"
        }
      ]
    }
  ],
  "total_entities": 456,
  "extraction_date": "2026-02-01T08:29:51.238013+00:00"
}